UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) (Address of principal executive offices including zip code) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE ...

FINANCE OF AMERICA REPORTS SECOND QUARTER 2025 RESULTS – $3.16 in basic earnings per share or $80 million of net income from continuing operations for the quarter – The financial information presented in the highlights is for the Company's continuing operations. (2) Graham A. Fleming, Chief Executive Officer commented, "Finance of America delivered another strong quarter, funding $602 million in loans and achieving our fifth consecutive quarter of growth. Our second quarter results reflect consistent execut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission file number: 001-36870 TopBuild Corp. (Exact name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12 ...

Exhibit 99.1 Upstart Announces Results for Second Quarter 2025 SAN MATEO, Calif. – August 5, 2025 – Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, today announced financial results for the quarter ended June 30, 2025. Upstart will host a conference call and webcast at 1:30 p.m. Pacific Time today. An earnings presentation and link to the webcast are available at ir.upstart.com. "A year ago, you saw the first signs that Upstart was returning to growth mod ...

August 5, 2025 Exhibit 99.1 Zeta Global Reports 16 th Straight "Beat and Raise" Quarter NEW YORK – Zeta Global (NYSE: ZETA), the AI Marketing Cloud, today announced financial results for the second quarter ended June 30, 2025. "We delivered another quarter of industry-leading growth, fueled by demand for our AI-powered marketing platform," said David A. Steinberg, Co-Founder, Chairman, and CEO of Zeta. "As we head into the back half of 2025, our AI-driven momentum on the heels of the Zeta Answers release, n ...

Exhibit 99.1 Financial News Release GAAP net income from continuing operations was $25.5 million or $0.67 per diluted share in the quarter, compared with $24.9 million or $0.65 per diluted share in the prior quarter, and $15.4 million or $0.41 per diluted share in the second quarter of 2024. Non-GAAP net income was $56.6 million or $1.50 per diluted share in the second quarter of 2025. This compares with $46.9 million or $1.23 per diluted share in the prior quarter, and $32.0 million or $0.85 per diluted sh ...

Exhibit 99.1 BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total second quarter revenue, comprised of $71.5 million of U.S. Attruby® net product revenue, $1.6 million from royalty revenue, and $37.5 million in license and services ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 28, 2025 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-32833 TransDigm Group Incorporated Delaware (State or other jurisdiction of incorporation or organization) 41-2101738 (I.R.S. ...